Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amarin Corp ADR (NQ: AMRN )

0.8752 -0.0065 (-0.74%)
Streaming Delayed Price Updated: 12:53 PM EDT, Sep 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Amarin Corp ADR

< Previous 1 2 3 4 5 Next >
Amarin to Present at the 2023 Cantor Global Healthcare Conference
From Amarin Corporation plc
Via GlobeNewswire
Amarin Provides Pricing & Reimbursement Updates for VAZKEPA (icosapent ethyl) in The Netherlands and Italy
From Amarin Corporation plc
Via GlobeNewswire
Amarin And Neopharm Announce Exclusive Commercialization Agreement for VAZKEPA® (Icosapent Ethyl) in Israel
From Amarin Corporation plc
Via GlobeNewswire
Scottish Medicines Consortium Accepts VAZKEPA® (icosapent ethyl) to Help Reduce Cardiovascular Risk for Patients in Scotland(1)
From Amarin Corporation plc
Via GlobeNewswire
Amarin Reports Second Quarter 2023 Financial Results
From Amarin Corporation plc
Via GlobeNewswire
Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea
Collaboration Broadens Reach of VAZKEPA to Additional Ten Countries Leveraging Lotus’ Established Commercial and Marketing Expertise in the Region 
From Amarin Corporation plc
Via GlobeNewswire
Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress
From Amarin Corporation plc
Via GlobeNewswire
Amarin Receives Positive Recommendation from Spanish Drug Pricing Committee for National Reimbursement of VAZKEPA® (icosapent ethyl) in Spain
From Amarin Corporation plc
Via GlobeNewswire
Amarin Board of Directors Announces Executive Compensation Program for New President and CEO Patrick Holt
From Amarin Corporation plc
Via GlobeNewswire
Amarin Appoints Patrick Holt as President and Chief Executive Officer
From Amarin Corporation plc
Via GlobeNewswire
Amarin Implements Organizational Restructuring to Strengthen the Company While Driving Patient Access to VASCEPA®/VAZKEPA® Globally
From Amarin Corporation plc
Via GlobeNewswire
Amarin Announces Vascepa® (Icosapent Ethyl) Approved to Reduce Cardiovascular Risk in the Kingdom of Saudi Arabia (KSA)
From Amarin Corporation plc
Via GlobeNewswire
Amarin to Present at Two Upcoming Investor Conferences
From Amarin Corporation plc
Via GlobeNewswire
Amarin Partner EddingPharm Receives Regulatory Approval for Vascepa® (Icosapent Ethyl) in Mainland China
From Amarin Corporation plc
Via GlobeNewswire
Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events
From Amarin Corporation plc
Via GlobeNewswire
Amarin Reports First Quarter 2023 Financial Results and Provides Business Update
From Amarin Corporation plc
Via GlobeNewswire
Amarin to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023
From Amarin Corporation plc
Via GlobeNewswire
Amarin Names Aaron Berg Interim President & Chief Executive Officer and Adds Oliver O’Connor to Company’s Board of Directors
From Amarin Corporation plc
Via GlobeNewswire
Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel's Ministry of Health
From Amarin Corporation plc
Via GlobeNewswire
Reconstituted Amarin Board Ready for the Challenge of Unlocking True Potential of VASCEPA®/VAZKEPA® (Icosapent Ethyl)
From Amarin Corporation plc
Via GlobeNewswire
Amarin Announces Board Departures
From Amarin Corporation plc
Via GlobeNewswire
Amarin Highlights New Evidence of Therapeutic Value of EPA in Reducing Cardiovascular Events in At-Risk Patients Presented at ACC.23/WCC
From Amarin Corporation plc
Via GlobeNewswire
Amarin Announces New REDUCE-IT® Data at ACC.23/WCC Showing Benefit of VASCEPA®/VAZKEPA® (Icosapent Ethyl) in High-Risk Patients with a Recent Acute Coronary Syndrome Event
From Amarin Corporation plc
Via GlobeNewswire
Amarin Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Amarin Corporation plc
Via GlobeNewswire
Sarissa Capital Wins Proxy Contest Against Amarin by Huge Landslide
From Sarissa Capital Management LP
Via Business Wire
Amarin Announces Preliminary Voting Results Following 2023 General Meeting of Shareholders
From Amarin Corporation plc
Via GlobeNewswire
Amarin and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA® (Icosapent Ethyl) in Australia and New Zealand
From Amarin Corporation plc
Via GlobeNewswire
Amarin Sets the Record Straight on Sarissa’s Latest Misstatements
From Amarin Corporation plc
Via GlobeNewswire
Amarin Corporation to Present New Data Evaluating VASCEPA®/VAZKEPA® (Icosapent Ethyl) at ACC.23/WCC
Presentations on Additional REDUCE-IT® Sub-Population, In-Vitro Data on EPA to Be Featured at the Congress 
From Amarin Corporation plc
Via GlobeNewswire
Sarissa Capital Condemns Amarin Board for Frontrunning Results of Proxy Contest With Egregious Equity Grants to Executives
From Sarissa Capital Management LP
Via Business Wire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.